- Home
- MSFT vs REVBW Comparison
MSFT vs REVBW Comparison
Compare MSFT & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSFT
- REVBW
- Stock Information
- Founded
- MSFT 1975
- REVBW N/A
- Country
- MSFT United States
- REVBW United States
- Employees
- MSFT N/A
- REVBW 9
- Industry
- MSFT Computer Software: Prepackaged Software
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- MSFT Technology
- REVBW Health Care
- Exchange
- MSFT Nasdaq
- REVBW Nasdaq
- Market Cap
- MSFT N/A
- REVBW N/A
- IPO Year
- MSFT 1986
- REVBW 2020
- Fundamental
- Price
- MSFT $429.03
- REVBW $0.01
- Analyst Decision
- MSFT Strong Buy
- REVBW
- Analyst Count
- MSFT 30
- REVBW 0
- Target Price
- MSFT $511.07
- REVBW N/A
- AVG Volume (30 Days)
- MSFT 19.0M
- REVBW N/A
- Earning Date
- MSFT 01-29-2025
- REVBW N/A
- Dividend Yield
- MSFT 0.77%
- REVBW N/A
- EPS Growth
- MSFT 17.35
- REVBW N/A
- EPS
- MSFT 12.11
- REVBW N/A
- Revenue
- MSFT $254,190,000,000.00
- REVBW N/A
- Revenue This Year
- MSFT $15.84
- REVBW N/A
- Revenue Next Year
- MSFT $14.23
- REVBW N/A
- P/E Ratio
- MSFT $35.43
- REVBW N/A
- Revenue Growth
- MSFT 16.44
- REVBW N/A
- 52 Week Low
- MSFT $385.58
- REVBW N/A
- 52 Week High
- MSFT $468.35
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- MSFT 51.24
- REVBW N/A
- Support Level
- MSFT $410.72
- REVBW N/A
- Resistance Level
- MSFT $434.32
- REVBW N/A
- Average True Range (ATR)
- MSFT 7.61
- REVBW 0.00
- MACD
- MSFT -0.13
- REVBW 0.00
- Stochastic Oscillator
- MSFT 74.73
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).